Figure 1.
Plasma concentration–time curves of gliclazide in CYP2C9*1/*1 subjects (n = 13) (□), CYP2C9*1/*3 subjects (n = 8) (
) and CYP2C9*1/*13 subjects (n = 3) (
) after a single oral dose of 30 mg of gliclazide MR. All data indicate mean ± SE
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.